This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Klimek VM . Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 2013; 20: 137–143.
Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 2013; 121: 2996–3004.
Pasquini MC, Zhu X . Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR summary slides. 2015 Available at: http://www.cibmtr.org.
Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850–1857.
Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542–549.
Finke J, Schmoor C, Bertz H, Marks R, Wäsch R, Zeiser R et al. Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, (e-pub ahead of print 11 January 2016; doi:10.1038/bmt.2015.338).
Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E et al. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst 2014; 106: djt462.
Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2340–2347.
Sidana S, Elson P, Gerds AT, Carraway HE, Advani AS, Saunthararajah Y et al. Survival outcomes of leukemias and myelodysplastic syndromes occurring as second cancers in the United States: a SEER registry-based population analysis. Blood 2015; 126: 2507.
Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol 2014; 32: 2691–2698.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Mukherjee, S., Gerds, A. Long-term survival of patients with therapy-related myeloid neoplasms after allogeneic hematopoietic cell transplantation—more than just a myth. Bone Marrow Transplant 51, 763–764 (2016). https://doi.org/10.1038/bmt.2016.121
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.121